Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Latest Information Update: 11 Jan 2022
At a glance
- Drugs Pevonedistat (Primary) ; Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- 16 Dec 2021 Status changed from active, no longer recruiting to discontinued.
- 28 Sep 2021 Planned End Date changed from 31 Mar 2024 to 5 Nov 2021.
- 28 Sep 2021 Status changed from recruiting to active, no longer recruiting.